Mechanisms of resistance to EGFR tyrosine kinase inhibitors: implications for patient selection and drug combination strategies

摘要: The receptor for epidermal growth factor (EGFR, ErbB1, HER1) supports the and maintenance of a broad range human tumor types, EGFR-targeting drugs are approved treatment several advanced stage cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, squamous head neck (SCCHN), colorectal cancer. Recent years have witnessed significant advances in our understanding dysregulated signal transduction cells resulting from changes expression and/or mutational status key signaling molecules that modulate sensitivity to targeting EGFR. Based on this knowledge, we an exciting opportunity maximize benefit provided patients by EGFR inhibitors. In review article, describe molecular determinants or resistance EGFR-targeted agents, with specific emphasis tyrosine kinase inhibitors (TKIs). impact these findings ability evaluate candidate predictive biomarkers design robust mechanism-based combination strategies is also discussed.